Shares of Scribe Therapeutics Inc., a clinical-stage developer focused on gene therapies for heart disease, closed soaring 44.33% on Friday after raising $128.7 million in an expanded IPO
Shares of Scribe Therapeutics Inc., a clinical-stage developer focused on gene therapies for heart disease, closed soaring 44.33% on Friday after raising $128.7 million in an expanded IPO. Affiliates of Sanofi SA have agreed to buy about $7.5 million in shares at the IPO price as part of a concurrent private placement, documents show. Eli Lilly, one of Scribe's existing backers, has expressed interest in buying more shares in the IPO to hold up to 11% of Scribe following the offering and placement.